Altimmune Initiates PERFORMA Phase 3 in MASH, Reports Positive AUD Data, and Bolsters Cash to $519M

What happened

Altimmune announced the initiation of its global PERFORMA Phase 3 MASH trial, positive topline data from the RECLAIM Phase 2 trial in alcohol use disorder (AUD), and completed enrollment in the RESTORE Phase 2 trial in alcoholic liver disease (ALD), alongside a robust cash position of $519 million as of June 30, 2026. These milestones directly address the key catalysts identified in the DeepValue master report—MASH Phase 3 start, AUD data, and funding visibility—and shift the risk-reward profile toward the bull scenario. The $519 million cash balance comfortably exceeds prior estimates and provides a multi-year runway, significantly reducing near-term dilution risk. Positive AUD data adds a new, potentially large indication and strengthens the case for pemvidutide as a multi-indication liver and metabolic franchise. With MASH Phase 3 underway and capital concerns alleviated, the investment thesis now commands higher conviction, though biopsy-proven fibrosis benefit and obesity partnership terms remain critical long-term unknowns.

Implication

The initiation of PERFORMA and positive AUD data materially advance pemvidutide’s clinical profile, while the $519 million cash balance provides ample runway to fund ongoing trials without imminent dilution. This progress increases the probability of successful MASH registration and enhances the asset’s appeal to potential partners, which could unlock additional non-dilutive funding for obesity Phase 3. However, the crucial biopsy-driven MASH Phase 3 readout remains years away, and Altimmune must still define its obesity partnership strategy to maximize value. Investors should consider increasing position sizes within risk tolerance, as the risk-reward skew has improved, with a clear path to $9–$12 per share if execution continues. The binary risk of late-stage failure persists, but current catalysts justify a more constructive stance.

Thesis delta

The thesis has strengthened materially—MASH Phase 3 initiation removes a key execution overhang, positive AUD data validates the broader liver franchise, and the $519 million cash position mitigates capital concerns. This shifts the base-case probability upward and reduces the bear-case risk, justifying higher conviction in the investment thesis. The market is now likely to reprice the stock toward the $9–$12 range over the next 12–24 months as these milestones are absorbed.